EMA RWE Pediatric Pilot & CMS Rebate Shift

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, today's topics feel particularly timely given the recent regulatory shifts we're seeing globally.

MarcusSame here. We're looking at the EMA's new pediatric RWE pilot for rare diseases — which could reshape how we generate evidence for underserved populations. Then the ISPOR 2026 conference focus on PRO frameworks — signaling a fundamental shift in value assessment methodologies. And CMS's proposed Medicaid rebate modifications — potentially altering manufacturer pricing strategies at scale.

SaraThat CMS rebate proposal is immediately interesting to me — the budget impact implications for state Medicaid programs could be substantial, especially with the proposed changes to manufacturer reporting requirements.

MarcusExactly. Let's get into it.

MarcusThe EMA just launched a pilot program to integrate real-world evidence into pediatric drug development, specifically targeting rare diseases where traditional trials struggle. This isn't just about data collection; it's about creating structured pathways for RWE to supplement clinical data in regulatory submissions.

SaraWhat strikes me is the operationalization challenges. How will they ensure data quality across different health systems? And how will HTA bodies incorporate this evidence when their methodologies are often anchored in RCTs?

MarcusThat's the crux. The EMA is emphasizing standardized data collection protocols and centralized repositories. But I wonder if that's the full picture though — pediatric rare diseases often have such small patient populations that even centralized data might not yield robust endpoints.

SaraFair point. The part that gives me pause is the heterogeneity within rare disease populations. A single RWE framework might not capture the nuanced differences between ultra-rare conditions and more common rare diseases.

MarcusTrue. But what's innovative here is the focus on patient registries as primary data sources. That could bridge the evidence gap if they establish clear governance around data sharing.

SaraAnd from the payer side, the question will be whether HTA bodies adjust their cost-effectiveness models to account for RWE-derived outcomes. The NICE precedent with Duchenne muscular dystrophy RWE comes to mind, but that was post-approval.

MarcusExactly. This pilot could set a precedent for pre-approval evidence generation. We'll need to watch how the EMA balances innovation with methodological rigor.

MarcusShifting to ISPOR 2026, the conference agenda highlights a significant evolution in PRO frameworks. It's not just about collecting patient-reported data anymore; it's about integrating PROs as primary endpoints in value assessments.

SaraThat connects to something I keep coming back to — the growing tension between regulatory endpoints and what truly matters to patients. ISPOR seems to be pushing for PROs to carry more weight in reimbursement decisions.

MarcusI'd push back slightly on that framing. The shift isn't about replacing clinical endpoints but creating hybrid models. The key development is the emphasis on minimally important difference thresholds in economic modeling.

SaraThat's one read — I'd frame it differently. Payers are increasingly skeptical of PROs due to recall bias and lack of standardization. The real story is HTA bodies starting to demand PRO validation studies alongside clinical data.

MarcusValid point. But what's striking here is the move toward digital PRO collection via wearables. That could address some validity concerns through real-time data capture.

SaraThe budget impact question there is one the field hasn't fully worked out yet. How do you value a PRO endpoint measured by a proprietary device versus a standardized questionnaire?

MarcusThat's precisely why the ISPOR framework includes digital PRO governance guidelines. They're trying to create common standards across different tech platforms.

SaraWe'll see if that translates into consistent HTA acceptance. The history of PROs in value assessment shows how difficult it is to achieve cross-jurisdictional alignment.

MarcusCMS just proposed sweeping changes to the Medicaid Drug Rebate Program, including new manufacturer reporting requirements and potential rebate recalculations based on actual utilization. This could fundamentally alter how manufacturers price drugs in the Medicaid space.

SaraWhat immediately catches my attention is the proposed shift from Average Manufacturer Price (AMP) to Actual Acquisition Cost (AAC) for some products. That would directly impact rebate calculations and manufacturer net pricing.

MarcusExactly. The AAC approach mirrors Part D pricing models, which could create more consistent rebates across Medicare and Medicaid. But I wonder if that's the full picture though — how will this affect orphan drug pricing strategies where rebates already create complex access challenges?

SaraThat's fair, though I think payers would see it differently. The AAC model could actually increase rebates for high-cost drugs, potentially improving budget predictability for state Medicaid programs.

MarcusThe operational burden is significant too. Manufacturers would need to track actual acquisition costs across multiple distribution channels, which wasn't required under the AMP system.

SaraAnd the proposed changes to manufacturer reporting timelines — from quarterly to monthly — would increase compliance costs substantially. That's one area where smaller manufacturers might struggle.

MarcusThat connects to something I keep coming back to — the disproportionate impact on biotech companies with limited commercial infrastructure. These changes could accelerate consolidation in the market access space.

SaraThe budget impact for state Medicaid programs could be mixed. While rebates might increase for some products, the administrative costs of implementation might offset those savings.

MarcusFinally, the Health Technology Assessment International (HTAI) and IQVIA have launched a global real-world evidence database designed to harmonize data across jurisdictions. This is an ambitious attempt to create standardized RWE for cross-border submissions.

SaraWhat strikes me is the geopolitical dimension. How will they navigate data privacy regulations like GDPR and HIPAA in a unified platform? The operational complexity seems immense.

MarcusThat's precisely why they're federating the data rather than centralizing it. Each country maintains its own data silos, but the analytical framework allows for cross-jurisdictional comparisons.

SaraI'd frame it slightly differently. The real value proposition is for manufacturers submitting to multiple HTA bodies simultaneously. Having pre-harmonized RWE could reduce evidence generation timelines significantly.

MarcusThe part that gives me pause is the governance structure. Who decides which endpoints are standardized? And how do they account for differences in healthcare systems that affect RWE interpretation?

SaraThat's one read — I'd argue the bigger challenge will be getting HTA bodies to trust and accept this common dataset. NICE has historically been skeptical of externally generated evidence.

MarcusFair point. But the EMA's recent acceptance of federated networks in the DARWIN EU project suggests regulatory bodies are becoming more open to such approaches.

SaraWe'll need to see how this plays out in practice. The history of global RWE initiatives shows how difficult it is to achieve true standardization.

SaraA lot to think about today. I'll be watching how CMS's Medicaid rebate proposal evolves through the comment period — particularly the AAC implementation timeline.

MarcusSame — and for me the thread running through today is the growing tension between innovation in evidence generation and the operational realities of regulatory acceptance. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.